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Dr James Tweddell (Milwaukee, Wis). I would like to thank
The American Association for Thoracic Surgery (AATS) for
asking me to discuss this report. Chris, that was really a terrific pre-
sentation. You and your colleagues have explored the STS
Congenital Heart Surgery Database for information on mechanical
support among patients undergoing congenital heart surgery.
Among almost 97,000 operations, the rate of MCS was 2.8%, or
2750 cases. Of these 2750 patients, 17% received support preoper-
atively, 78% postoperatively, and 5% were fortunate enough to
receive both preoperative and postoperative circulatory support.
More than 95% of the patients were supported using ECMO;
thus, we can really consider this a study of perioperative ECMO
support.
Not surprisingly, the patients receiving MCS were younger,
smaller, and more likely to have the preoperative risk factors of
shock, in particular, mechanical ventilation and arrhythmias, and
were more likely to require more complex procedures.
Just to be clear, to be included in the present study, there must
have been an operation for congenital heart disease. Thus, patients
admitted with acute myocarditis or dilated cardiomyopathy or
receiving mechanical support as a bridge to recovery or transplan-
tation would not have been included, is that correct?
Dr Mascio. That is correct.
Dr Tweddell. In addition, as you said, we do not have data on
the indications for mechanical support such as inotrope score or
any surrogates or measures of cardiac output or the use of cardio-
pulmonary resuscitation (CPR) at the timemechanical support was
initiated.
Dr Mascio. Correct. The database did not track the inotrope
score, measures of cardiac output, or the use of CPR during the
study period (2000-2010).
Dr Tweddell. What was most dramatic to me was the plot of
MCS use versus center volume. Naively, perhaps, I would have
anticipated that larger volume centers would have used MCS
less than would lower volume centers. The center variation was
tremendous. This really illuminates the dramatic differences in
practice patterns among centers. If you have seen 1 congenital
heart surgery program, you have seen 1 congenital heart surgery
program.
Did you explore any of the variations in practice patterns?
Could you tell us whether a difference existed in the
complexity–adjusted survival rates of MCS between those pro-
grams using MCS frequently and those using it very little?
DrMascio.We compared theMCS rate with the volume but did
not examine survival at high versus low use centers.
Dr Tweddell. Was there a difference in survival between the
high- and low-volume centers with MCS?
Dr Mascio. We do not know from the present study. A slight
difference was present in the rate of mechanical support, but it
was likely not clinically significant.
Dr Tweddell. You stated in your report, which was very well-
written, that you studied the regional differences in the United
States—northeast, south, west, et cetera. Did you see any differ-
ences or any consistency in the MCS used in the different regions?
DrMascio.We examined the location, but not the regional rate
of use of MCS, of the 80 included centers.ery c February 2014
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DDr Tweddell. Well, overall, the mortality was >50% and
certainly MCS in the perioperative setting is expensive and highly
morbid. Clearly, we need some additional information on the indi-
cations for MCS. The next few questions really concern how we
should proceed next.
Would you recommend that we add some data fields to the STS
database in the future? Keeping in mind the substantial burden of
the number of fields we already have.
Dr Mascio. Yes, I would. In fact, in the newest STS database
form they have already added fields, including the type of assist de-
vice, the indication for initiation, and the reason for termination of
support. Starting this summer, that form will be used and that
information will be tracked.
Dr Tweddell. You also mentioned the ELSO database. Do you
think there is an opportunity to go back with these data and the
ELSO registry, such as Sara Pasquali has done for antifibrinolytics,
to determine whether we can at least tease out who was receiving
CPR at ECMO initiation?
Dr Mascio. I think so, because those 2 databases follow
different data points. The ELSO database definitely has an extra-
corporeal CPR group that they follow and they also follow postop-
erative complications after ECMO. So I think using both databases
can certainly provide us with some data that each one individually
could not.
Dr Tweddell.Do you think it would beworthwhile trying to put
together some sort of survey of North American centers to identify
the indications forMCS?We could thenmatch the indications with
outcomes and potentially identify the best practices?
Dr Mascio. Yes, absolutely—and not just for indications, but
for management also. For example, for anticoagulation manage-
ment, some centers use anti-Xa levels, some centers use the acti-
vated clotting time, some centers use the partial thromboplastin
time, and some use a combination of all of those.
Dr Tweddell. That was an excellent presentation. Just as with
all very good reports, you have identified more questions for us
to answer in the future. Thank you.
Dr Mascio. Thank you very much.
Dr V. Mohan Reddy (Stanford, Calif). Chris, I have 1 question
for you. In your analysis, considering ECMO and the length of
ECMO, was there any duration of ECMO beyond which it was
futile and was discontinued?
DrMascio.The STS database during the 2000 to 2010 period did
not follow that; thus,wedo not know the reason for the initiation and/
or termination or the duration of support. We just know the patients
had undergone an index operation that was followed by MCS.
DrReddy. Thus, obviously, if it was just a pure myocardial fail-
ure and the patient is receiving ECMO for that, I would suspect
that beyond a certain period the myocardium is unlikely to recover.
DrMascio. From our findings, we could not really state that af-
ter 48 or 72 hours, or any duration for that matter, that ECMO
should be discontinued. The end point we considered was in-hos-
pital mortality.
Dr Reddy. I think it would be worthwhile data to gather from
any database, because it would be important to know that beyond
a certain period it is not worth continuing it.The Journal of Thoracic and CaDr Mascio. I agree.
Dr Christian Pizarro (Wilmington, Del). Very nice presenta-
tion. Do you have any data that can help us understand why was
it that although the Norwood patients tended to be supported
more often, some of those complex ventricular repairs had the
highest mortality? Also, if not, could you elaborate from what
you know how that could be explained?
Dr Mascio. From the present study, no. Others have reported
truncus arteriosus repair and Ross-Konno operation as very
high-risk operations. In the present study, Norwood mortality,
even without mechanical support, was 13%. The present study
cannot explain why mechanical support for some biventricular re-
pairs was associated with very high mortality.
Dr Carl L. Backer (Chicago, Ill). Chris, congratulations on a
terrific study. As Dr Tweddell said, this review might have opened
up more questions than answers. However, it is important and eye-
opening to realize that there is a 57% mortality rate for putting a
patient on ECMO after a Norwood procedure. Many centers now
experience external pressures on cost containment and I believe
that at some point, we might not be able to afford this therapy. It
will be up to us to decide who is going to receive ECMO and
who is not, from both a quality of life standpoint and a careful
use of resources standpoint. We are going to have to somehow
figure this out.
I agree that the idea of a survey proposed by Dr Tweddell is a
very good one. Perhaps we could then develop consensus-based
guidelines for using ECMO in the postoperative period. At some
centers, no patient dies without first receiving ECMO. We need
to decide whether this is in the best interest of the patient and
the family. Consider a neonate with heterotaxy, total veins, pulmo-
nary atresia, an unbalanced atrioventricular septal defect, and
severe postoperative atrioventricular valve insufficiency. Perhaps
that patient should not be receiving ECMO automatically for
severe ventricular dysfunction after the operation. It will be incum-
bent on us as a group to determine this before external forces tell us
when we can and cannot use ECMO. Do you have any thoughts on
this socioeconomic issue?
Dr Mascio. I think that doing a survey is a very good idea.
When we were writing our report, we were careful to use the
phrase ‘‘receiving mechanical support’’ and not ‘‘requiring me-
chanical support.’’ Because, as you said, it is different for every
institution. Some institutions use ECMO for all patients, and
some would take a patient such as you just described and not offer
MCS.
Dr V.Mohan Reddy (Stanford, Calif). I think it might probably
be worthwhile to have a task force similar to the American Heart
Association task force that can develop guidelines for ECMO,
when to start and whom to start and when to discontinue. It might
be something the Association might consider.
Further Discussion by James Tweddell, MD
Dr Tweddell (Milwaukee, Wis). The last comment, the rate of
ECMO support for the Norwood procedure was 17% in the present
study, which goes back many years; 15% in the Single Ventricle
Reconstruction trial. Thus, I think it is pretty much within the
range of what many institutions experience.rdiovascular Surgery c Volume 147, Number 2 665
